Literature DB >> 18602077

Administration of beta-glycolipids overcomes an unfavorable nutritional dependent host milieu: a role for a soy-free diet and natural ligands in intrahepatic CD8+ lymphocyte trapping and NKT cell redistribution.

Dan M Livovsky1, Gadi Lalazar, Ami Ben Ya'acov, Orit Pappo, Sarah Preston, Lidya Zolotaryova, Yaron Ilan.   

Abstract

UNLABELLED: Soy-based diets are a major source of sphingolipids and play a complicated role in various aspects of the immune system. Administration of beta-glycolipids, including beta-glucosylceramide (GC), beta-lactosylceramide (LC) and a 1:1 combination of GC and LC (IGL) were shown to exert immune-modulatory effects. AIM: To examine the effects of a soy-free diet, and several beta-glycolipids on concanavalin A (ConA)-induced hepatitis in the presence of an altered host glycolipid milieu.
METHODS: ConA hepatitis was induced in C57BL/6 mice that were fed a soy-free diet (glycolipid content 200 micromol/kg). Two hours prior to administration of ConA, animals were injected IP with GC, LC, IGL or PBS. Animals were sacrificed 6 h after ConA administration.
RESULTS: Both a soy-free diet and administration of beta-glycolipids were associated with significant alterations in the distribution of NKT cells. Specifically, there was a decrease in intrahepatic and an increase in intrasplenic NKT lymphocytes. beta-glycolipids prevented the ConA-induced intrahepatic CD8 lymphocyte trapping, not seen in mice with only a soy-free diet. Both a soy-free diet and beta-glycolipids alleviated ConA-induced hepatitis by inhibiting IL10 secretion and increasing IL12 serum levels. The effect of IGL was clinically and immunological superior to that of either glycolipid alone.
CONCLUSIONS: Both a soy-free diet and beta-glycolipids can overcome the unfavorable host milieu in the setting of ConA hepatitis. The host glycolipid milieu profoundly influenced the immune and clinical effects of various insults, and suggests that alteration of the glycolipid background of the host can serve as a novel therapeutic tool.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602077     DOI: 10.1016/j.intimp.2008.05.005

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  5 in total

1.  Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance.

Authors:  Tawfik Khoury; Ami Ben Ya'acov; Yehudit Shabat; Lidya Zolotarovya; Ram Snir; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

2.  Personalized inherent randomness of the immune system is manifested by an individualized response to immune triggers and immunomodulatory therapies: a novel platform for designing personalized immunotherapies.

Authors:  Madi El-Haj; Dimitri Kanovitch; Yaron Ilan
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

3.  Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for "Safer Drug" Formulation that Prevents Drug-induced Liver Injury.

Authors:  Meir Mizrahi; Tomer Adar; Gadi Lalazar; Dean Nachman; Madi El Haj; Ami Ben Ya'acov; Yoav Lichtenstein; Yehudit Shabat; Dimitri Kanovich; Lida Zolotarov; Yaron Ilan
Journal:  J Clin Transl Hepatol       Date:  2018-02-14

4.  Oral Co-administration of Soy-derived Extracts with Alcohol or with Sugar-sweetened Beverages Exerts Liver and Sugar Protective Effects.

Authors:  Tawfik Khoury; Devorah Rotnemer-Golinkin; Yehudit Shabat; Lidya Zolotarovya; Yaron Ilan
Journal:  J Clin Transl Hepatol       Date:  2017-06-03

5.  The role of the sphingosine axis in immune regulation: A dichotomy in the anti-inflammatory effects between sphingosine kinase 1 and sphingosine kinase 2-dependent pathways.

Authors:  Yuval Ishay; Dvorah Rotnemer-Golinkin; Yaron Ilan
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.